Painceptor Pharma gains patent for lead drug
PainCeptor Pharma Corp., a biopharmaceutical company focused on the development of novel therapeutics for the treatment of chronic and acute pain, announced that it has been awarded a series of milestone patents for its two lead drug development programs, NGF (nerve growth factor) and ASIC (acid sensing ion channel) antagonists.
The four patents granted PainCeptor are:
1. 'Neurotrophin Antagonists for the Treatment of Epilepsy, Alzheimer's Disease and Pain'' - patent allowed in Europe (#0930883) and Israel (#129475)
2. 'Method of Inhibiting Neurotrophin-Receptor Binding'' - patent issued in Australia (#781888)
3. "DNA Encoding a Human Proton-Gated Ion Channel and Uses Thereof'' - patent allowed in Europe (#EP-B-1025226)
4. "Method of Inhibiting Neurotrophin-Receptor Binding'' - US Divisional Patent allowed
These patents bring the total of PainCeptor's intellectual property portfolio to 39 issued patents; with an additional 45 patent applications under examination; and a further 10 provisional applications pending.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.